Financials in USD. Standardized financial statements.
A compact view of how Venus Medtech (Hangzhou) Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Revenue? | $298.87M | $470.83M | $491.37M | $406.46M | $415.86M | $276.05M | $233.27M |
| Revenue Growth? | -36.5% | -4.2% | +20.9% | -2.3% | +50.6% | +18.3% | 0.0% |
| Cost of Revenue? | $161.83M | $103.09M | $102.17M | $92.46M | $91.52M | $48.77M | $38.61M |
| Gross Profit? | $137.04M | $367.75M | $389.20M | $314.00M | $324.34M | $227.28M | $194.66M |
| Gross Margin? | +45.9% | +78.1% | +79.2% | +77.3% | +78.0% | +82.3% | +83.4% |
| Operating Expenses? | $474.22M | $714.34M | $977.75M | $948.88M | $596.30M | $405.89M | $573.36M |
| Operating Income? | -$337.18M | -$346.60M | -$589.97M | -$650.21M | -$278.64M | -$178.61M | -$328.04M |
| EBITDA? | -$242.36M | -$612.96M | -$547.84M | -$999.37M | -$324.03M | -$145.97M | -$352.29M |
| Income Before Tax | -$394.44M | -$740.71M | -$735.34M | -$1.16B | -$377.56M | -$185.84M | -$381.54M |
| Income Tax Expense | $2.73M | -$23.34M | -$6.28M | -$34.30M | -$6.16M | -$2.98M | -$778,000 |
| Net Income? | -$397.17M | -$714.31M | -$703.75M | -$1.06B | -$373.64M | -$181.99M | -$380.72M |
| EPS? | $-0.91 | $-1.63 | $-1.61 | $-2.42 | $-0.85 | $-0.44 | $-1.22 |
| Diluted EPS? | $-0.91 | $-1.63 | $-1.61 | $-2.42 | $-0.85 | $-0.44 | $-1.22 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality